Expanding Access to Ultra-Sensitive Biomarker Testing: Urine as a Non-Invasive Matrix for Simoa Assays

Urine as a Non-Invasive Matrix for Ultra-Sensitive Biomarker Detection with Simoa®

The Simoa® platform extends its unmatched sensitivity to urine, enabling detection of low-abundance neurological and infectious disease biomarkers in a non-invasive, easy-to-collect matrix.

This application note highlights:

Detection of brain-specific proteins (NfL, t-tau, GFAP, UCH-L1) in stroke patient urine
A TB assay in urine with 98% specificity in HIV+ individuals

Simoa supports both ready-to-use and custom assays, making urine-based testing ideal for pediatric, geriatric, and global health research.

Download the full application note to explore how Simoa makes biomarker science more accessible than ever.

First Name

Last Name

Company

What type of organization is your company?

Country

State

Postal Code

Phone

I would like to receive emails about Quanterix’s products and services. I consent

Comments

By submitting the form you agree to Quanterix’s Terms and Conditions. If you have subscribed to our email marketing you can unsubscribe at any time, and you can learn more about how we manage your personal details in our Privacy Policy.

APP NOTE

Expanding Access to Ultra-Sensitive Biomarker Testing: Urine as a Non-Invasive Matrix for Simoa Assays

Urine as a Non-Invasive Matrix for Ultra-Sensitive Biomarker Detection with Simoa®

You might also like

Saliva as a Noninvasive Matrix for Immune Surveillance and Infectious Disease Research via Ultra-Sensitive Antibody Detection

Beyond Blood: Expanding Simoa Applications in Urine, Saliva, Sweat, & Tears

Decoding Alzheimer’s: The History, Biomarkers, and Clinical Advances